Apollon Wealth Management LLC Grows Stake in Johnson & Johnson $JNJ

Apollon Wealth Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 18.0% in the 1st quarter, HoldingsChannel.com reports. The firm owned 134,086 shares of the company’s stock after purchasing an additional 20,418 shares during the quarter. Apollon Wealth Management LLC’s holdings in Johnson & Johnson were worth $32,776,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Pasadena Private Wealth LLC lifted its holdings in shares of Johnson & Johnson by 1.9% in the 1st quarter. Pasadena Private Wealth LLC now owns 3,672 shares of the company’s stock valued at $898,000 after buying an additional 69 shares during the period. Riverbend Wealth Management LLC lifted its holdings in Johnson & Johnson by 3.5% in the first quarter. Riverbend Wealth Management LLC now owns 5,436 shares of the company’s stock valued at $1,329,000 after acquiring an additional 182 shares during the period. Canoe Financial LP grew its stake in shares of Johnson & Johnson by 41.4% during the 1st quarter. Canoe Financial LP now owns 715,018 shares of the company’s stock worth $174,779,000 after purchasing an additional 209,449 shares during the period. Red Door Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 0.4% during the 1st quarter. Red Door Wealth Management LLC now owns 65,657 shares of the company’s stock valued at $16,049,000 after purchasing an additional 256 shares in the last quarter. Finally, Bay Capital Advisors LLC purchased a new stake in Johnson & Johnson during the first quarter worth $201,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Guggenheim increased their target price on shares of Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. JPMorgan Chase & Co. raised their price objective on Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective for the company in a research report on Wednesday, May 13th. Argus increased their target price on Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Finally, Barclays lifted their price target on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $256.70.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson is strengthening its cancer franchise with positive European regulatory news for Tecvayli in combination with Darzalex SC, plus a planned acquisition of Firefly Bio to expand its oncology pipeline. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Positive Sentiment: Management reiterated that J&J is prioritizing cancer and neuroscience rather than entering the obesity drug market, which signals a disciplined capital-allocation strategy and a clearer long-term growth plan. Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy
• Positive Sentiment: J&J is being featured by multiple outlets as a top dividend and income stock, and technical commentary says the shares are breaking out past a buy point, which may be encouraging momentum-oriented investors. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Neutral Sentiment: Analysts are focusing on upcoming Q2 Innovative Medicine results, with Stelara biosimilar pressure expected to offset some growth from newer therapies; investors may be waiting for earnings confirmation before pushing the stock higher. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Neutral Sentiment: Recent market coverage notes that J&J has already had a strong one-year rally, so some investors are now weighing whether the valuation still offers upside from here. Johnson & Johnson (JNJ) Stock After 73% One-Year Rally Is There Value Left

Johnson & Johnson Stock Performance

JNJ opened at $253.76 on Thursday. Johnson & Johnson has a twelve month low of $154.21 and a twelve month high of $259.90. The firm has a market capitalization of $610.86 billion, a PE ratio of 29.34, a PEG ratio of 2.49 and a beta of 0.24. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The firm’s 50-day moving average price is $232.26 and its 200 day moving average price is $230.68.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business’s revenue was up 9.9% on a year-over-year basis. During the same period last year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were paid a $1.34 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.